Cue Biopharma Debt
| CUE Stock | USD 1.02 0.01 0.97% |
Cue Biopharma holds a debt-to-equity ratio of 0.332. At present, Cue Biopharma's Total Debt To Capitalization is projected to increase slightly based on the last few years of reporting. . Cue Biopharma's financial risk is the risk to Cue Biopharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Cue Biopharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Cue Biopharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Cue Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Cue Biopharma's stakeholders.
For most companies, including Cue Biopharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Cue Biopharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Cue Biopharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 2.5474 | Book Value 0.785 | Operating Margin (3.91) | Return On Assets (0.52) | Return On Equity (1.39) |
Cue |
Cue Biopharma Bond Ratings
Cue Biopharma financial ratings play a critical role in determining how much Cue Biopharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Cue Biopharma's borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (3.44) | Unlikely Manipulator | View |
Cue Biopharma Debt to Cash Allocation
Many companies such as Cue Biopharma, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Cue Biopharma has 14.7 M in debt with debt to equity (D/E) ratio of 0.33, which is OK given its current industry classification. Cue Biopharma has a current ratio of 8.12, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Cue to invest in growth at high rates of return. Cue Biopharma Total Assets Over Time
Cue Biopharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Cue Biopharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Cue Biopharma Debt Ratio | 13.0 |
Cue Biopharma Corporate Bonds Issued
Most Cue bonds can be classified according to their maturity, which is the date when Cue Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Cue Net Debt
Net Debt |
|
Understaning Cue Biopharma Use of Financial Leverage
Cue Biopharma's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Cue Biopharma's total debt position, including all outstanding debt obligations, and compares it with Cue Biopharma's equity. Financial leverage can amplify the potential profits to Cue Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Cue Biopharma is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Net Debt | -33.8 M | -35.5 M | |
| Short and Long Term Debt Total | 14.7 M | 10.9 M | |
| Short and Long Term Debt | 4 M | 3.1 M | |
| Short Term Debt | 7.3 M | 7.1 M | |
| Long Term Debt | 4.2 M | 4.9 M | |
| Long Term Debt Total | 7.2 M | 6.4 M | |
| Net Debt To EBITDA | 0.73 | 0.70 | |
| Debt To Equity | 0.22 | 0.21 | |
| Interest Debt Per Share | 0.21 | 0.20 | |
| Debt To Assets | 0.13 | 0.13 | |
| Long Term Debt To Capitalization | 0.10 | 0.10 | |
| Total Debt To Capitalization | 0.18 | 0.22 | |
| Debt Equity Ratio | 0.22 | 0.21 | |
| Debt Ratio | 0.13 | 0.13 | |
| Cash Flow To Debt Ratio | (4.89) | (5.14) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out the analysis of Cue Biopharma Fundamentals Over Time. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.